Evidence map›Paper›PMID 38494565›Full record

Trial reportAnnals of surgical oncology2024

Leg Lymphoedema After Inguinal and Ilio-Inguinal Lymphadenectomy for Melanoma: Results from a Prospective, Randomised Trial.

T S Lee, I Li, B Peric, R P M Saw, J P Duprat, E Bertolli, J B Spillane, B L van Leeuwen, M Moncrieff, A Sommariva and 6 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

T S LeeMelanoma Institute Australia, Wollstonecraft, Sydney, Australia. teresa.lee@melanoma.org.au.ORCID http://orcid.org/0000-0001-8815-9515
I LiMelanoma Institute Australia, Wollstonecraft, Sydney, Australia.ORCID http://orcid.org/0009-0002-0039-7274
B PericMedical Faculty, Institute of Oncology Ljubljana, University of Ljubljana, Ljubljana, Slovenia.ORCID http://orcid.org/0000-0001-7228-8267
R P M SawMelanoma Institute Australia, Wollstonecraft, Sydney, Australia.ORCID http://orcid.org/0000-0002-3354-806X
J P DupratAC Camargo Cancer Center, São Paulo, Brazil.ORCID http://orcid.org/0000-0001-8968-4506
E BertolliAC Camargo Cancer Center, São Paulo, Brazil.ORCID http://orcid.org/0000-0003-1412-0436
J B SpillaneDepartment of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
B L van LeeuwenSurgical Oncology, University Medical Center Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0002-6745-4424
M MoncrieffNorfolk & Norwich University Hospital, Plastic and Reconstructive Surgery, Norwich, UK.ORCID http://orcid.org/0000-0003-4492-235X
A SommarivaVeneto Institute of Oncology IOV-IRCCS, Surgical Oncology, Padua, Italy.ORCID http://orcid.org/0000-0002-5764-5606
C P AllanFaculty of Medicine, Mater Clinic School, University of Queensland, Brisbane, Australia.ORCID http://orcid.org/0000-0001-9209-3125
J H W de WiltDepartment of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0001-6773-9668
R Pritchard- JonesMersey and West Lancashire Teaching Hospitals NHS Trust, Prescot, Knowsley, UK.ORCID http://orcid.org/0000-0002-0549-7146
J L C GehDepartment of Plastic and Reconstructive Surgery, St Thomas' Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0001-7031-3844
J R HowleUniversity of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0003-3634-246X
A J SpillaneMelanoma Institute Australia, Wollstonecraft, Sydney, Australia.ORCID http://orcid.org/0000-0002-8354-434X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Evaluation of Groin Lymphadenectomy Extent for Melanoma (EAGLE FM) study sought to address the question of whether to perform inguinal (IL) or ilio-inguinal lymphadenectomy (I-IL) for patients with inguinal nodal metastatic melanoma who have no clinical or imaging evidence of pelvic disease. Primary outcome measure was disease-free survival at 5 years, and secondary endpoints included lymphoedema.

methodsEAGLE FM was designed to recruit 634 patients but closed with 88 patients randomised because of slow recruitment and changes in melanoma management. Lymphoedema assessments occurred preoperatively and at 6, 12, 18, and 24 months postoperatively. Lymphoedema was defined as Inter-Limb Volume Difference (ILVD) > 10%, Lymphoedema Index (L-Dex

resultsPrevalence of leg lymphoedema between the two groups was similar but numerically higher for I-IL at all time points in the first 24 months of follow-up; highest at 6 months (45.9% IL [CI 29.9-62.0%], 54.1% I-IL [CI 38.0-70.1%]) and lowest at 18 months (18.8% IL [CI 5.2-32.3%], 41.4% I-IL [CI 23.5-59.3%]). Median ILVD at 24 months for those affected by lymphoedema was 14.5% (IQR 10.6-18.7%) and L-Dex

conclusionsDespite a trend for patients who had I-IL to have greater lymphoedema prevalence than IL in the first 24 months after surgery, our study's small sample did not have the statistical evidence to support an overall difference between the surgical groups.

Indexed as

Inguinal CanalLymphedemaLymph Node ExcisionMelanomaSkin NeoplasmsAdultAgedFemaleFollow-Up StudiesHumansLegMaleMiddle AgedNeoplasm StagingPostoperative ComplicationsPrognosis

Identifiers

PMID38494565
PMCPMC11076360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.